TABLE 1.

DDI boundaries (magnitude of inhibition or induction) at which the error in ignoring EH for intravenous administration of commonly used victim drugs exceeds ±30% for predicted AUC ratio and intestinal contribution to a DDI and the error in estimated f_{m, CYPi} when EH is ignored for intravenously administered victim drugs

Victim Drug	EH	f m, CYPi	f hep	F G	AUC′IV/AUCIV Error ≥±30%		Clint, GI′/Clint, GI Error ≥±30%		Ignoring EH for Determination of fm, CYPi
					Inhibition I/Ki or λ/kdeg ≥	Fold Induction ≥	Inhibition I/Ki or λ/kdeg ≥	Fold Induction ≥	fm, CYPi Ignoring EH	%Error in Maximum Oral AUC Ratio (−fm, CYPi · EH · 100)
CYP3A
Midazolam	0.44 a	0.93 b	0.995 c	0.54 a	1.3	2.1	0.37	1.5	0.90	−41
Alfentanil	0.28 d	0.98 d	0.99	0.59 d	9.0	2.6	0.54	1.6	0.96	−27
Nifedipine	0.45 b	0.78 e	0.99	0.74 b	2.0	2.3	0.25	1.3	0.65	−35
CYP2C9
Tolbutamide	0.01 f	0.78 b	1	N.A.	Not possible	56	N.A.		0.78	−0.8
S-Warfarin	0.003 g	0.91 b	1	N.A.	Not possible	160	N.A.		0.91	−0.3
CYP2D6
Desipramine	0.48 h	0.88 i	1	N.A.	0.9	2.0	N.A.		0.79	−42
Imipramine	0.70 j	0.46 i	1	N.A.	2.6	2.3	N.A.		0.20	−32
Metoprolol	0.84 k	0.83 i	1	N.A.	0.5	1.6	N.A.		0.44	−70
Propranolol	0.62 l	0.37 i	1	N.A.	Not Possible	2.9	N.A.		0.18	−23

N.A., not applicable.

^a Data from Thummel et al. (1996).

^b Data from Obach et al. (2006).

^c Data from Midazolam HCL Injection package insert (Baxter Healthcare, Deerfield, IL).

^d Data from Kharasch et al. (2004).

^e Data from Ohno et al. (2007).

^f Data from Miners et al. (1982).

^g Data from Abernethy et al. (1991).

^h Data from Ciraulo et al. (1988).

ⁱ Data from Ito et al. (2005).

^j Data from Abernethy et al. (1984).

^k Data from Leemann et al. (1993).

^l Data from Feely et al. (1981).